DEFTA Partners

DEFTA Partners

DEFTA Partners

Date Founded



111 Pine Street,Suite 1410,San Francisco, CA 94111-5616

Type of Company


Employees (Worldwide)

1 - 10


Private Equity & Venture Capital
IT Consulting & Services
Hospitals & Patient Services
Investment Services & Portfolio Management

Company Description

DEFTA Corp. invests in companies located in U.S., U.K., Israel, Bangladesh, and Japan. The firm focuses on companies operating in the fields of medical devices, IT, healthcare services. They provide financing for seed and early stage capital requirements.

Contact Data
Trying to get in touch with decision makers at DEFTA Partners? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees


Venture Partner


Paths to DEFTA Partners
Potential Connections via
Relationship Science
DEFTA Partners
Recent Transactions
Details Hidden

Intel Corp. purchases Oplus Technologies Ltd. from Benchmark Capital Management Co. LLC, Giza Venture Capital, BRM Capital Advisors Ltd., DEFTA Partners, Challenge Partners

Political Donations
Details Hidden

Coyote Pharmaceuticals, Inc. operates a biopharmaceutical company. It focuses on creating high value therapeutics for large unmet medical needs in several therapeutic categories including neurodegenerative, cardiovascular, oncologic, and inflammatory diseases. The company was founded by Hiroaki Serizawa in 2009 and is headquartered in Menlo Park, CA.

Details Hidden

Nihon CLOUDFILING Corp. engages in the provision of storage, management, and browsing services of documents in the cloud environment. The firm offers cloud type form which includes public and private, and on-premise type form which is installed in the designated general-purpose data center. The company was founded on December 20, 2011 and is headquartered in Toshima-ku, Japan.

Details Hidden

Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by DEFTA Partners. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of DEFTA Partners's profile does not indicate a business or promotional relationship of any kind between RelSci and DEFTA Partners.